Tobias Kiesslich , Christian Mayr , Dino Bekric , Daniel Neureiter
{"title":"对DLBCL中可能的HDAC抑制剂耐药的新见解——Havas等人对“定义对HDAC选择性抑制剂的细胞反应表明,需要有效靶向HDAC3来引发细胞毒性并克服naïve弥漫性大B细胞淋巴瘤中泛hdaci的耐药”的评论。","authors":"Tobias Kiesslich , Christian Mayr , Dino Bekric , Daniel Neureiter","doi":"10.1016/j.tranon.2023.101820","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"44 ","pages":"Article 101820"},"PeriodicalIF":5.0000,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1936523323002061/pdfft?md5=92c597a36046d1538f250d75caac3162&pid=1-s2.0-S1936523323002061-main.pdf","citationCount":"0","resultStr":"{\"title\":\"New insights into possible HDAC inhibitor resistance in DLBCL - Comment on 'defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve resistance to pan-HDACi in diffuse large B cell lymphoma' by Havas et al.\",\"authors\":\"Tobias Kiesslich , Christian Mayr , Dino Bekric , Daniel Neureiter\",\"doi\":\"10.1016/j.tranon.2023.101820\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":48975,\"journal\":{\"name\":\"Translational Oncology\",\"volume\":\"44 \",\"pages\":\"Article 101820\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2023-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1936523323002061/pdfft?md5=92c597a36046d1538f250d75caac3162&pid=1-s2.0-S1936523323002061-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1936523323002061\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523323002061","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
New insights into possible HDAC inhibitor resistance in DLBCL - Comment on 'defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve resistance to pan-HDACi in diffuse large B cell lymphoma' by Havas et al.
期刊介绍:
Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.